Menu Content
How may we help?
I am a new caregiver
I need information
I need a laugh
Home
News
New Study From Rhode Island Hospital Confirms Previous Reports and Raises New Questions
Wednesday, 23 January 2008

A new study by researchers at Rhode Island Hospital and Brown University finds that people with Alzheimer's Disease (AD) experienced more accidents and performed more poorly on road tests compared to drivers without cognitive impairment. The study is published in the January 23 edition of Neurology, the medical journal of the American Academy of Neurology.


While the study does confirm previous reports of potentially hazardous driving in persons with early AD, it also indicates that some individuals with very mild dementia can continue to drive safety for extended periods of time. The study included 128 individuals—84 with early AD and 44 age-matched control subjects without cognitive impairments. Drivers with early AD were enrolled in this study and followed every six months over two to three years.


Under the direction of principal investigator Brian Ott, M.D., director of the Alzheimer’s Disease and Memory Disorders Center at Rhode Island Hospital and professor at The Warren Alpert Medical School of Brown University, the study looked at driving abilities through self-reports, family reports and a standardized road test.


The study results indicate that people with early AD experienced more accidents and performed more poorly on road tests when compared to participants without cognitive impairments. “We also found that people with what is defined as mild dementia were significantly more likely to fail a road test than those defined with very mild dementia.”


Ott says, “Our findings showed that people with mild dementia were nearly four times more likely to fail a road test than those with very mild dementia, indicating that people with very mild dementia may be able to drive safely for longer periods of time.”


Ott notes, “It is clear, however, that driving ability declines fairly rapidly among patients with dementia, and therefore, regular follow-up assessments are warranted in these people with very mild dementia.” Currently, the American Academy of Neurology Guideline on Risk of Driving and Alzheimer’s Disease recommends a reassessment every six months for those patients diagnosed with very mild dementia who continue to drive.


The study also found increased age as well as lower education can impact driving abilities. Ott comments, “The odds of failing a road test increased by about six percent for every year exceeding the age of 75.” The study found that drivers who lagged behind the average education experience within the study group were likely to fail a road test; failure was 10 percent more likely for each year in which they lagged behind the average education experience of 14 years.


Of interest, the frequency of motor vehicle accidents in the AD drivers declined during the study. Overall, Ott says, “The results suggest that a regular driving assessment program may actually reduce the frequency of motor vehicle accidents in drivers with mild dementia by increasing awareness among the driver and caregivers. This, however, may also result in premature termination of driving privileges for some persons with dementia.” The researchers note that this is a major challenge facing clinicians: to develop valid and reliable office screening tools, which can assist the clinician with making driving assessment referrals and recommendations regarding driving safety for those with early AD.


The study was funded by a grant from the National Institute on Aging. The researchers recently announced the grant has been renewed to fund the study for another four years.

Source: Lifespan

 
Protein 'fingerprint' in spinal fluid could spot Alzheimer's Disease
Monday, 24 December 2007

23-protein screen is highly accurate and first to be validated

ITHACA, N.Y. -- Scientists collaborating at Cornell University in Ithaca and Weill Cornell Medical College in New York City have identified a panel of 23 protein biomarkers in cerebrospinal fluid that acts as a neurochemical "fingerprint," which doctors might use someday to identify patients living with Alzheimer's disease.The research will be published in the December online-edition of the journal Annals of Neurology.

Right now, physicians rely on their clinical judgment to decide whether a particular patient has Alzheimer's rather than some other form of dementia. In many cases, the diagnosis remains uncertain until brain tissue is examined at autopsy.

"Our study is the first to use sophisticated proteomic methods to hone in on a group of cerebrospinal fluid biomarkers that are specific to autopsy-proven Alzheimer's disease. Those postmortem tests confirmed that the panel is over 90 percent sensitive in identifying people with Alzheimer's disease," says Kelvin Lee, the Samuel C. and Nancy M. Fleming Professor of Molecular and Cell Biology and associate professor of chemical and biomolecular engineering at Cornell.

Researchers at a variety of centers have long sought biomarkers in blood or cerebrospinal fluid that identify the presence of Alzheimer's pathology and distinguish it from other conditions that cause dementia.

"Some of these studies have met with limited success, but most have correlated their findings with patient's clinical symptoms rather than working with the gold-standard of autopsy-proven Alzheimer's," notes Norman Relkin, M.D., associate professor of clinical neurology and neuroscience at Weill Cornell and director of the Memory Disorders Program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
Read more...
 
Third Party Japanese Study Suggests Drug Improves Memory
Monday, 17 December 2007
Sarasota's Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimer's Disease Research

Sarasota, Fla. The Roskamp Institute announced December 14th that its promising new drug application for the treatment of Alzheimer's disease has received positive validation from an independent human clinical study conducted at the Tokyo Medical University in Japan. The study, which suggests the drug, Nilvadipine, can prevent the onset of Alzheimer's disease in patients with memory problems, is detailed in the International Journal of Geriatric Psychiatry, a highly prestigious medical research journal.

The Japanese study was conducted over the course of a 20-month period, where a group of 15 amnestic mild cognitive impairment (MCI) patients with essential hypertension were divided into two groups. A group of eight participants were randomly allocated to take the drug Nilvadipine, while the other seven remaining participants were designated to take the drug Amlodipine.
 
The study found that the group treated with Nilvadipine had stabilized their decline in memory over the 20 months; whereas, the group treated with Amlodipine had continued to suffer loss of cognitive function, which was double that of the small decline in the Nilvadipine controlled group. 
Read more...
 
'Alzheimer's Gene' Linked To Increased Risk of Postoperative Delirium
Tuesday, 28 August 2007

Adapted from the American Society of Anesthesiologists

Elderly patients who carry a gene associated with an increased risk of Alzheimer's disease and dementia have higher rates of postoperative delirium after major surgery.

The September issue of the journal Anesthesiology features a study linking the apolipoprotein e4 (APOE e4)) gene variant to the risk of postoperative delirium, a common postoperative complication in elderly patients. Previous population studies have suggested that the APOE e4 gene variant is associated with an increased risk of developing the late-onset form of Alzheimer's disease (developing after age 65), and cognitive decline.
Read more...
  << Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 73 - 80 of 87

Inside the Brain:
An Interactive Tour

braintour.gif
Courtesy of the:
alzheimers-association.gif
My site was nominated for Best Health Blog! HealthCentral Top Site AwardCFA_logo_winner.jpg
© Copyright 2010 The KnowItAlz Group. Site Map.
RSS Feeds: Entries - News - Comments
Web design by plethoradesign.com